Jpmorgan Chase & CO Apellis Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 423,800 shares of APLS stock, worth $8.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

423,800

Previous 411,549 2.98%

Holding current value

$8.3 Million

Previous $13.1 Million 29.42%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$21.87 - $34.63 $267,929 - $424,252	12,251 Added 2.98%	423,800 $9.27 Million
Q4 2024 Feb 12, 2025	SELL	$26.18 - $35.42 $90.9 Million - $123 Million	-3,473,181 Reduced 89.41%	411,549 $13.1 Million
Q3 2024 Dec 26, 2024	BUY	$28.84 - $41.15 $20.4 Million - $29.1 Million	707,260 Added 22.26%	3,884,730 $112 Million
Q3 2024 Nov 08, 2024	BUY	$28.84 - $41.15 $20.4 Million - $29.1 Million	707,260 Added 22.26%	3,884,730 $112 Million
Q2 2024 Dec 26, 2024	SELL	$38.07 - $59.71 $26.9 Million - $42.2 Million	-707,260 Reduced 18.21%	3,177,470 $122 Million
Q2 2024 Aug 12, 2024	BUY	$38.07 - $59.71 $36.7 Million - $57.5 Million	963,161 Added 43.5%	3,177,470 $122 Million
Q1 2024 Dec 26, 2024	SELL	$55.39 - $72.47 $92.5 Million - $121 Million	-1,670,421 Reduced 43.0%	2,214,309 $130 Million
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $19.9 Million - $26.1 Million	-359,824 Reduced 13.98%	2,214,309 $130 Million
Q4 2023 Dec 26, 2024	SELL	$37.14 - $64.82 $48.7 Million - $85 Million	-1,310,597 Reduced 33.74%	2,574,133 $154 Million
Q4 2023 Feb 12, 2024	BUY	$37.14 - $64.82 $13.2 Million - $23.1 Million	356,386 Added 16.07%	2,574,133 $154 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $10.2 Million - $38.4 Million	430,765 Added 24.11%	2,217,747 $84.4 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $10.6 Million - $12.9 Million	138,530 Added 8.4%	1,786,982 $163 Million
Q1 2023 May 18, 2023	BUY	$46.59 - $66.96 $5.79 Million - $8.33 Million	124,357 Added 8.16%	1,648,452 $109 Million
Q1 2023 May 11, 2023	SELL	$46.59 - $66.96 $15.1 Million - $21.6 Million	-323,214 Reduced 17.5%	1,524,095 $101 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $39.2 Million - $55.4 Million	907,262 Added 96.51%	1,847,309 $95.5 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $5.99 Million - $9.33 Million	-133,918 Reduced 12.47%	940,047 $64.2 Million
Q2 2022 Aug 11, 2022	SELL	$35.07 - $59.21 $6.74 Million - $11.4 Million	-192,273 Reduced 15.18%	1,073,965 $48.6 Million
Q1 2022 May 11, 2022	SELL	$35.46 - $54.12 $11.4 Million - $17.4 Million	-321,640 Reduced 20.26%	1,266,238 $64.3 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $1.68 Million - $2.69 Million	54,736 Added 3.57%	1,587,878 $75.1 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $48.1 Million - $107 Million	1,533,142 New	1,533,142 $50.5 Million

Others Institutions Holding APLS

# of Institutions

287

Shares Held

124M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.15B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Apellis Pharmaceuticals, Inc. Transaction History